Show simple item record

dc.contributor.authorAnderson, Heather
dc.contributor.authorHasleton, Philip S
dc.contributor.authorMichie, A B
dc.contributor.authorJohnson, Richard J
dc.contributor.authorThatcher, Nick
dc.date.accessioned2010-07-21T15:17:53Z
dc.date.available2010-07-21T15:17:53Z
dc.date.issued1988-01
dc.identifier.citation24-hour cyclophosphamide infusion therapy for malignant mesothelioma of the pleura. 1988, 82 (1):64-9 Br J Dis Chesten
dc.identifier.issn0007-0971
dc.identifier.pmid3166920
dc.identifier.doi10.1016/0007-0971(88)90009-5
dc.identifier.urihttp://hdl.handle.net/10541/108101
dc.description.abstractThirteen patients with malignant mesothelioma of the pleura have been treated with 24-hour cyclophosphamide infusion (2.5 g/m2) therapy. There were no complete responders. Three patients (23%) had a partial response, and a further three patients who did not fulfil the criteria for objective response, had subjective benefit from therapy with increase in performance status. The overall median survival from the onset of therapy was 6 months (range 2-19 months). High dose cyclophosphamide offers no advantage over standard dose therapy.
dc.language.isoenen
dc.subjectPleural Canceren
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshCyclophosphamide
dc.subject.meshDrug Administration Schedule
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshInfusions, Parenteral
dc.subject.meshLung
dc.subject.meshMale
dc.subject.meshMesothelioma
dc.subject.meshMiddle Aged
dc.subject.meshPleural Neoplasms
dc.title24-hour cyclophosphamide infusion therapy for malignant mesothelioma of the pleura.en
dc.contributor.departmentCRC Department of Medical Oncology, Christie Hospital, Manchester.en
dc.identifier.journalBritish Journal of Diseases of the Chesten
html.description.abstractThirteen patients with malignant mesothelioma of the pleura have been treated with 24-hour cyclophosphamide infusion (2.5 g/m2) therapy. There were no complete responders. Three patients (23%) had a partial response, and a further three patients who did not fulfil the criteria for objective response, had subjective benefit from therapy with increase in performance status. The overall median survival from the onset of therapy was 6 months (range 2-19 months). High dose cyclophosphamide offers no advantage over standard dose therapy.


Files in this item

This item appears in the following Collection(s)

Show simple item record